Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01903057
Other study ID # IRB00065751
Secondary ID ITI2012-001
Status Withdrawn
Phase Phase 4
First received July 15, 2013
Last updated May 21, 2014
Start date February 2014
Est. completion date July 2014

Study information

Verified date May 2014
Source Emory University
Contact n/a
Is FDA regulated No
Health authority Mozambique: Ministry of Health (MISAU)United States: Institutional Review BoardUnited States: Data and Safety Monitoring Board
Study type Interventional

Clinical Trial Summary

Trachoma and lymphatic filariasis (LF) are two 'Neglected Tropical Diseases' (NTDs), infectious diseases that affect millions of poor people in countries in the developing world. Trachoma is an eye infection that can lead to painful scarring of the eyelids and blindness later in life. LF can lead to swelling of usually the limbs (elephantiasis).

Trachoma and LF are preventable and treatable diseases. One important treatment strategy is annual Mass Drug Administration (MDA): Communities receive drug treatment once a year. Azithromycin is given for trachoma. Ivermectin and albendazole are given for LF.

Trachoma MDA and LF MDA are currently separated campaigns. Combined MDA campaigns for trachoma and LF, where three drugs would be given at one time, would reduce costs and decrease the burden on the health system.

Before combined MDA with three drugs (azithromycin, ivermectin and albendazole) could be recommended, we would have to demonstrate that the safety profile of this treatment with three drugs is acceptable. An earlier study in Mali in 2010 (AZIVAL) comparing standard MDA (one week space between the two MDA campaigns) with combined MDA (trachoma and LF MDA on the same day) showed that the safety profiles were comparable; but the results of the study were not statistically significant and we could not use them to make an official recommendation.

The AZIVAL 2 study has been designed to answer the questions that remain after the AZIVAL study performed in Mali in 2010. If the safety results of the AZIVAL 2 study are acceptable, an official recommendation for combined MDA with azithromycin, ivermectin and albendazole can be drafted.

We will conduct the AZIVAL 2 study in Mozambique. The target population (inclusion and exclusion criteria) is the same as in the AZIVAL study in Mali. Main criteria are: Age ≥ 5 years and ≤ 65 years, height ≥ 90 cm, if female, not pregnant or breast-feeding.

Important differences between the AZIVAL study and the AZIVAL 2 study are a) smaller clusters for sufficient power (average household size is 5 people), b) placebo to double-blind participants and study staff for azithromycin, c) the study area will have undergone fewer previous rounds of MDA for LF and none for trachoma, and d) smartphones for data entry.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2014
Est. primary completion date March 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 5 Years to 65 Years
Eligibility Inclusion Criteria:

- Age = 5 years and = 65 years.

- Height = 90 cm

- Able to understand the information and consent and assent forms, willing to give consent and assent, and abide by the study restrictions (parent or guardian consent if study participant age is < 18 years, participant to assent form if age < 18 years and = 7 years)

- Residence in the study site for at least three months prior to enrolment

- Willing to remain in the study site for the duration of the study

- Willing and able to provide necessary samples to permit evaluation.

Exclusion Criteria:

- Unable to swallow tablets

- History of hypersensitivity/allergy to azithromycin, ivermectin, and/or albendazole

- Treatment with another investigational agent/intervention within 4 weeks prior to study entry

- Pregnancy (demonstrated by positive urine pregnancy test, performed by study staff, or evidently pregnant). All women of child bearing age (= 12 years and = 49 years in Nampula province, personal communication, Arlinda Martins) will undergo a urine pregnancy test (unless they are evidently pregnant) to exclude pregnancy.

- Breast-feeding mother.

- Any condition that, in the opinion of the investigator, might interfere with the outcome of the study and/or adherence to the follow up schedule, such as clinically significant illness.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)


Related Conditions & MeSH terms


Intervention

Drug:
azithromycin

ivermectin

albendazole

placebo


Locations

Country Name City State
Mozambique National Institute of Health, Ministry of Health Maputo

Sponsors (1)

Lead Sponsor Collaborator
Emory University

Country where clinical trial is conducted

Mozambique, 

References & Publications (1)

Coulibaly YI, Dicko I, Keita M, Keita MM, Doumbia M, Daou A, Haidara FC, Sankare MH, Horton J, Whately-Smith C, Sow SO. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. PLoS Negl Trop Dis. 2013 May 9;7(5):e2221. doi: 10.1371/journal.pntd.0002221. Print 2013. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The overall rate of adverse events and serious adverse events in each group 15 days Yes
Secondary The types of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy. 15 days Yes
Secondary The incidences of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy. 15 days Yes
Secondary The timing of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy. 15 days Yes
Secondary The duration of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy. 15 days Yes
Secondary The intensities of adverse events and serious adverse events of triple combination therapy with azithromycin, ivermectin and albendazole, to standard sequential therapy. 15 days Yes
See also
  Status Clinical Trial Phase
Completed NCT03676140 - Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 3
Completed NCT01949454 - Fluorometholone as Ancillary Therapy for TT Surgery N/A
Completed NCT01202331 - Tripartite International Research for the Elimination of Trachoma Phase 4
Completed NCT05634759 - Enhancing the A in SAFE for Trachoma Phase 4
Recruiting NCT04185402 - Azithromycin Reduction to Reach Elimination of Trachoma Phase 4
Active, not recruiting NCT00886015 - Modified Instrumentation for Surgery to Correct Trichiasis Phase 3
Completed NCT00792922 - Partnership for Rapid Elimination of Trachoma Phase 4
Completed NCT00522860 - A Trial of Non-absorbable Versus Absorbable Sutures for Trichiasis Surgery Phase 4
Completed NCT00221364 - Trachoma Elimination Follow-up Phase 4
Completed NCT00322972 - Trachoma Amelioration in Northern Amhara (TANA) Phase 4
Withdrawn NCT00286026 - Azithromycin in Control of Trachoma II Phase 4
Completed NCT00347763 - Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania Phase 4
Terminated NCT03997487 - Smartphone App for Taking Images of Conjunctivae N/A
Terminated NCT04002726 - App-based Versus Slide-based Inter-grader Agreement (IGA) Test for Trachoma Graders N/A
Not yet recruiting NCT06289647 - Azithromycin Reduction to Reach Elimination of Trachoma B Phase 4
Withdrawn NCT02655432 - Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population Phase 0
Completed NCT01767506 - A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial N/A
Completed NCT00618449 - Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Phase 4
Completed NCT00356720 - Efficacy and Safety of 2 Dosing Regimens of T1225 Eye Drops 1.5% Versus Oral Azithromycin in Treatment of Trachoma Phase 3
Completed NCT03813069 - Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma Phase 2